-
公开(公告)号:US20100029575A1
公开(公告)日:2010-02-04
申请号:US12300610
申请日:2007-05-25
申请人: Jean-Louis Junien , Pierre J.M. Riviere , Claudio D. Schteingart , Javier Sueiras Diaz , Jerzy A. Trojnar , Todd W. Vanderah , Michael E. Lewis
发明人: Jean-Louis Junien , Pierre J.M. Riviere , Claudio D. Schteingart , Javier Sueiras Diaz , Jerzy A. Trojnar , Todd W. Vanderah , Michael E. Lewis
CPC分类号: C07K5/1016 , A61K38/00
摘要: Certain peptides which exhibit high selectivity for the kappa opioid receptor (KOR) versus the mu opioid receptor and little or no CYP3A4 inhibitory activity including tetrapeptides of four D-isomer amino acid residues having a C-terminus which is an N-oxide-substituted amide such, as H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl-N-oxide. A preferred compound, which has an affinity for the KOR at least 1,000 times its affinity for the mu opioid receptor and an IC50 for CYP3 A4 of greater than about 10 micromolar, is H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl-N-oxide
摘要翻译: 对于κ阿片样物质受体(KOR)与μ-阿片样物质受体显示出高选择性的某些肽,并且很少或没有CYP3A4抑制活性,包括具有C-末端的四个D-异构体氨基酸残基的四肽,其是N-氧化物取代的酰胺 如HD-Phe-D-Phe-D-Nle-D-Arg-NH-4-吡啶甲酰基-N-氧化物。 HD-Phe-D-Phe-D-Nle-D-D对于KOR具有对μ-阿片样物质受体的亲和力至少1000倍的亲和力以及大于约10微摩尔的CYP3A4的IC 50的优选化合物, Arg-NH-4-吡啶甲酰基-N-氧化物
-
公开(公告)号:US5965701A
公开(公告)日:1999-10-12
申请号:US997208
申请日:1997-12-23
申请人: Jean Louis Junien , Pierre J.M. Riviere , Claudio D. Schteingart , Javier Sueiras Diaz , Jerzy A. Trojnar , Todd W. Vanderah
发明人: Jean Louis Junien , Pierre J.M. Riviere , Claudio D. Schteingart , Javier Sueiras Diaz , Jerzy A. Trojnar , Todd W. Vanderah
IPC分类号: A61K38/00 , A61K38/07 , A61P1/04 , A61P13/00 , A61P13/10 , A61P25/04 , C07K5/10 , C07K5/107 , C07K5/117 , C07K5/00
CPC分类号: C07K5/1027 , C07K5/1016 , C07K5/1024 , A61K38/00
摘要: Peptides which exhibit high selectivity for the kappa opioid receptor (KOR) and long duration of peripheral action without significant entry into the brain are created which are sequences of four D-isomer amino acid residues having a C-terminus which is a mono or di-substituted amide. Representative compounds, which have an affinity for the KOR at least 1,000 times their affinity for the mu opioid receptor and an ED.sub.50 of not greater than about 0.5 mg/kg, includeH-D-Phe-D-Phe-D-Nle-D-Arg-NHEt,H-D-Phe-D-Phe-D-Nle-D-Arg-morpholinyl,H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl,H-D-Phe-D-Phe-D-Nle-D-Arg-NHPr,H-D-Phe-D-Phe-D-Nle-D-Arg-thiomorpholinyl,H-D-Phe-D-Phe-D-Nle-D-Arg-NEt.sub.2,H-D-Phe-D-Phe-D-Nle-D-Arg-NHMe,H-D-Phe-D-Phe-D-Leu-D-Orn-morpholinyl,H-D-Phe-D-Phe-D-Nle-D-Arg-NHhEt,H-D-Phe-D-Phe-D-Nle-D-Arg-NH-cyclopropyl,H-D-Ala(2Thi)-D-4Cpa-D-Leu-D-Arg-morpholinyl,H-D-Phe-D-Phe-D-Nle-D-Arg-piperidinyl,H-D-Phe-D-Phe-D-Leu-D-Orn-NHEt,H-D-Phe-D-Phe-D-Leu-D-Lys-morpholinyl,andH-D-Phe-D-Phe-D-Nle-D-Arg-piperazinyl.
摘要翻译: 产生对κ阿片样物质受体(KOR)具有高选择性且长期持续的外周作用而不显着进入脑的肽是具有C末端的四个D-异构体氨基酸残基的序列,其是单或二 - 取代的酰胺。 对KOR具有至少1,000次对μ阿片受体的亲和力和不大于约0.5mg / kg的ED 50的亲和力的代表性化合物包括H-D-Phe-D-Phe-D-Nle-D- Arg-NHEt,HD-Phe-D-Phe-D-Nle-D-Arg-吗啉基,HD-Phe-D-Phe-D-Nle-D-Arg-NH-4-吡啶甲基,HD-Phe- Phe-D-Nle-D-Arg-NHPr,HD-Phe-D-Phe-D-Nle-D-Arg-硫代吗啉基,HD-Phe-D-Phe-D-Nle-D-Arg-NEt2, Phe-D-Phe-D-Nle-D-Arg-NHMe,HD-Phe-D-Phe-D-Leu-D-Orn-吗啉基,HD-Phe-D-Phe-D-Nle-D-Arg- NHhEt,HD-Phe-D-Phe-D-Nle-D-Arg-NH-环丙基,HD-Ala(2Thi)-D-4Cpa-D-Leu-D-Arg-吗啉基,HD-Phe-D-Phe -D-Nle-D-Arg-哌啶基,HD-Phe-D-Phe-D-Leu-D-Orn-NHEt,HD-Phe-D-Phe-D-Leu-D-Lys-吗啉基和H-D -Phe-D-Phe-D-Nle-D-Arg-哌嗪基。
-
公开(公告)号:US08778881B2
公开(公告)日:2014-07-15
申请号:US13409976
申请日:2012-03-01
申请人: Kazimierz Wisniewski , Claudio Schteingart , Regent LaPorte , Robert Felix Galyean , Pierre J.M. Riviere
发明人: Kazimierz Wisniewski , Claudio Schteingart , Regent LaPorte , Robert Felix Galyean , Pierre J.M. Riviere
摘要: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.
摘要翻译: 本申请涉及新化合物,包含其的药物组合物,所述化合物在制备用于治疗特别是休克条件的药物中的用途以及治疗所述病症的方法,其中施用所述化合物。 化合物由通式(I)表示,如说明书中进一步定义的。
-
-